Abstract:Introduction The characterization of the mutational landscape of human cancers over the past 30 years has resulted in the rise of targeted cancer therapies. This era of precision oncology aims to enable cancer patients to receive therapies that are specific, efficacious, and result in fewer toxicities. A major challenge however is the emergence of drug resistance. Predicting resistance mechanisms using in vitro models can help to plan rational clinical trials using combination approaches and avoiding treating specific subtypes of cancers that are unlikely to respond. Here, we apply CRISPR screens in non-Hodgkin lymphoma (NHL) to predict resistance mechanisms and genetic synergies to EZH2 inhibitor (EZH2i) treatment. Materials and Methods Genome-wide CRISPR-Cas9 screens were performed in EZH2 'change-of-function' mutant and EZH2 wild-type patient-derived NHL cell lines, treated with either EZH2i or vehicle control. Validatory cell competition assays were then performed using individual CRISPR sgRNAs targeting specific genes of interest, including AEBP2 and NSD2. These sgRNAs were tagged with a green fluorescence protein enabling the identification of the knock-out population using flow cytometry. An additional CRISPR screen using a PRC2 'tiled' approach was also performed in the NHL cell lines to elucidate the essential domains within PRC2 proteins. Clonal knock out cells were generated using CRISPR and CUT&RUN experiments were performed for histone post-translational modifications in the knock-out cells to understand the mechanisms of resistance. Lastly, Quant-seq experiments were undertaken in the clonal knock out cells to characterise the transcriptional changes underlying the mechanism of resistance and sensitization observed with specific genetic knock outs. Results and Discussion We identified the NSD2 gene as a 'resistor' gene to EZH2i treatment, as sgRNAs targeting NSD2 were more abundant in the EZH2i treated cells compared to control cells. Conversely, the PRC2 accessory component AEBP2 was identified as a 'sensitizer' gene in this context. Cell competition assays using several independent sgRNAs to target the NSD2 and AEBP2 genes validated these findings. The EZH2i resistance phenotype was replicated using an orthogonal approach of pharmacological NSD2 degradation. These results point to the possibility of acquired loss of function mutations in NSD2 resulting in resistance to EZH2i in vivo. Finally, we explored the changes in transcriptional programs and H3K36 and H3K27 methylations across the genome. We propose a model for how NSD2 and AEBP2 loss confer resistance and sensitivity, respectively, to EZH2i in NHL cells. Conclusion We identified NSD2 loss as a potential mechanism by which NHL cells can acquire resistance to therapeutic EZH2i. We propose a potential solution of combining EZH2i treatment with targeted inhibition of AEBP2, thus preventing the occurrence of EZH2i resistance. Our work suggests that pharmacological inhibitors or degraders of AEBP2 should be prioritised for development. Citation Format: Daniel I Angelov, James Nolan, Grainne Holland, David Reck, Darragh Nimmo, Craig Monger, Elisabeth Vandenberghe, Adrian P Bracken. B-cell lymphoma CRISPR screens: NSD2 loss confers EZH2 inhibition resistance, while AEBP2 is a specific genetic dependency [abstract]. In: Proceedings of the Blood Cancer Discovery Symposium; 2024 Mar 4-6; Boston, MA. Philadelphia (PA): AACR; Blood Cancer Discov 2024;5(2_Suppl) nr P10.

Abstract 4799: Epigenetic Antagonism Between Polycomb and SWI/SNF Complexes During Oncogenic Transformation

Abstract LB-237: Epigenetic Antagonism Between Polycomb and SWI/SNF Complexes Duringoncogenic Transformation

Epigenetic Antagonism Between Polycomb and SWI/SNF Complexes During Oncogenic Transformation

Abstract 5240: Functional and Therapeutic Significance of ESR1 Gene Fusions in Breast Cancer

Abstract 830: ZFP14, a p53 target, suppresses tumor formation by regulating HOXA gene cluster expression

SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2

Abstract 1143: EZH2 Promotes Oral Squamous Cell Carcinoma Initiation and Progression Through Epigenetic Silencing of FHL1

Loss of SMARCB1 evokes targetable epigenetic vulnerabilities in Epithelioid Sarcoma

Transient loss of Polycomb components induces an epigenetic cancer fate

Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential

Epigenetic basis of oncogenic-Kras-mediated epithelial-cellular proliferation and plasticity

Histone methylation antagonism drives tumor immune evasion in squamous cell carcinomas

Abstract 2016: Combined targeting of epigenetic mechanisms has superior efficacy against human mantle cell lymphoma cells

The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors

Epigenomic regulation of oncogenesis by chromatin remodeling

Hypermethylation of CDKN2A CpG island drives resistance to PRC2 inhibitors in SWI/SNF loss-of-function tumors

Abstract 415: Keratin-fusion mutation promotes tumor aggressiveness via genomic instability induction

Abstract 1243: Shifted mSWI/SNF complex assembly and function underlie therapeutically targetable dependencies in endometrial carcinoma

Abstract P10: B-cell lymphoma CRISPR screens: NSD2 loss confers EZH2 inhibition resistance, while AEBP2 is a specific genetic dependency

Abstract LB060: Single-cell CRISPR screen of malignant peripheral nerve sheath tumors (MPNST)